Our Clinical Pipeline

Currently, four Inhibrx programs are in ongoing Phase 1 clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD).

The Candidates

Phase 1
Phase 2
Phase 3


Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

Orphan / Respiratory

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Learn more clinicaltrials.gov
Inbrx 101


Our Tetravalent DR5 Agonist


INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more Phase 1 Trial
Inbrx 109


Our Hexavalent OX40 Agonist


INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov
Inbrx 106


Our PD-L1 x 4-1BB Tetravalent Conditional Agonist


INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.

Learn more clinicaltrials.gov
Inbrx 105

Near-term Clinical Milestones

Milestones Graphic Lg

1. INBRX-109 (DR5) Initiation of chondrosarcoma registration-enabling trial

2. INBRX-106 (OX40 / Keytruda dose escalation data

3. INBRX-101 (AAT) Initial Phase 1 data

4. INBRX-105 (PD-L1 x 41BB) Keytruda dose-escalation data

5. INBRX-109 (DR5) Initial pancreatic and mesothelioma combination study data

6. INBRX-101 (AAT) Additional Phase 1 data

7. INBRX-109 (DR5) Ewing sarcoma combination study data

8. INBRX-106 (OX40) / Keytruda dose-expansion cohort data

9. INBRX-105 (PD-L1 x 41BB) Keytruda dose-expansion cohort data